Key opinion leaders close the discussion by discussing results of ongoing clinical trials presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting, regarding the use of perioperative therapy in patients with breast cancer.
Data from the following clinical trials are discussed:
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). (Khan, ASCO 2020 LBA2)
Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).(Wang, ASCO 2020 Abstract 507)
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (Harbeck, ASCO 2020 Abstract 500)
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. (van der Voort, ASCO 2020 Abstract 501)
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (Cardoso, ASCO 2020 Abstract 506)